Related Experiment Video

Updated: Apr 18, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.6K

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C

R K Sterling1, A Kuo, V K Rustgi

  • 1Virginia Commonwealth University Health System, Richmond, VA, USA.

Alimentary Pharmacology & Therapeutics
|January 29, 2015
PubMed

Insights

Direct-acting antiviral agents (DAAs) showed lower sustained virological response (SVR) rates in real-world HCV treatment compared to clinical trials. Patients without cirrhosis consistently achieved higher SVR rates, highlighting cirrhosis as a key factor influencing treatment outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pharmacology

Background:

  • The HCV-TARGET study is a longitudinal, observational research initiative involving a US consortium of 90 medical centers.
  • It focuses on patients with chronic hepatitis C virus (HCV) infection undergoing treatment with direct-acting antiviral agents (DAAs).

Purpose of the Study:

  • To evaluate the utilization of response-guided therapy (RGT).
  • To determine the sustained virological response (SVR) rates in a large cohort of HCV patients treated with early DAAs.

Main Methods:

  • Patients received a treatment regimen including peginterferon (PEG-IFN), ribavirin, and either telaprevir or boceprevir.
  • Demographical, clinical, and virological data were collected throughout treatment and follow-up periods.
  • Response-guided therapy (RGT) and treatment futility stopping rules were assessed at critical time points.

Main Results:

  • The study included 2084 patients; 38% had cirrhosis and 56% had prior HCV treatment.
  • SVR rates varied by DAA and cirrhosis status: Boceprevir (31% with cirrhosis, 50% without); Telaprevir (46% with cirrhosis, 60% without).
  • Predictors of SVR included early viral clearance, IL28B genotype, platelet count, and diabetes (boceprevir); and viral clearance, IL28B, cirrhosis, HCV subtype, age, hemoglobin, bilirubin, and albumin (telaprevir).

Conclusions:

  • Triple therapy with boceprevir or telaprevir yielded SVR rates lower than those reported in pivotal phase 3 clinical trials.
  • SVR rates were consistently higher in patients without cirrhosis compared to those with cirrhosis, irrespective of the DAA used or prior treatment history.
  • The study is registered at clinicaltrials.gov (NCT01474811).
Abstract

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.5K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.1K

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
1
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.8K
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
63
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
16.2K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820